BiomX(NYSEMKT) PHGE

BiomX develops treatments that use viruses called phages to target harmful bacteria. Its therapies aim to help people with chronic diseases like cystic fibrosis and certain skin conditions. These products are designed for patients who do not respond to standard antibiotics.

Bug Busters: Products and Services

• BX004 (Inhaled phage therapy): Treats lung infections in cystic fibrosis patients; no revenue contribution as of Q2 2025.
• BX211 (Phage for diabetic foot infections): Targets Staphylococcus aureus in diabetic wounds; no revenue contribution as of Q2 2025.
• BX003 (Oral phage cocktail): Aims at gut bacteria linked to inflammatory bowel disease and liver disease; no revenue contribution as of Q2 2025.
• Colorectal Cancer Program: Uses engineered phages to target bacteria in tumors; preclinical stage, no revenue as of Q2 2025.
• Personalized phage therapy: Custom treatments for joint infections; program currently on hold, no revenue as of Q2 2025.

Growing Pains and Gains: Expansion Moves

• Acquired Adaptive Phage Therapeutics in March 2024, expanding U.S. pipeline and assets.
• Launched Phase 2b trial for BX004 in cystic fibrosis in July 2025.
• Completed Phase 2 trial for BX211 in diabetic foot infections in 2025.
• Discontinued BX005 (atopic dermatitis) in 2024 to focus on core programs.
• Expanded clinical collaborations, including support for a U.S. National Institutes of Health study in cystic fibrosis.

Why BiomX Is a Bit Different

BiomX uses a proprietary platform to quickly develop phage therapies for hard-to-treat bacterial infections. The company combines broad-use and personalized approaches, aiming to address both common and rare patient needs. Its regulatory designations and U.S. expansion support its position in the clinical-stage phage therapy field.

Five Things You Need to Know

• Revenue was $0 in Q2 2025 and Q2 2024, but was negative $90,000 in Q2 2023.
• Operating loss was $7 million in Q2 2025, improving 23.6% from Q2 2024.
• Cash and equivalents were $14 million as of June 30, 2025, down 94.1% from Q2 2024.
• Net cash used in operations was $14.8 million for H1 2025, compared to $22.6 million for H1 2024.

Bottom Line

BiomX remains a pre-commercial company focused on developing phage-based therapies for chronic bacterial diseases. Its recent acquisitions and clinical progress show adaptability, but ongoing losses and funding needs remain key challenges.